A phase 3 randomized, placebo-controlled study assessing the efficacy and safety of epoetin-α in anemic patients with low-risk MDS.

P, Fenaux; V, Santini; MAA, Spiriti; A, Giagounidis; R, Schlag; A, Radinoff; L, Gercheva-Kyuchukova; A, Anagnostopoulos; EN, Oliva; A, Symeonidis; MH, Berger; KS, Götze; A, Potamianou; H, Haralampiev; R, Wapenaar; I, Milionis; U, Platzbecker

doi:10.1038/s41375-018-0118-9

Public

A phase 3 randomized, placebo-controlled study assessing the efficacy and safety of epoetin-α in anemic patients with low-risk MDS.

Shared by NobleBlocks on Mar 30, 2018 • 12:00 AM UTC

Authors:

Fenaux P

Santini V

Spiriti MAA

Abstract

Erythropoiesis-stimulating agents are first choice for treating anemia in low-risk MDS. This double-blind, placebo-controlled study assessed the efficacy and safety of epoetin-α in IPSS low- or intermediate-1 risk (i.e., low-risk) MDS patients with Hb ≤ 10.0 g/dL, with no or moderate RBC transfusion...

Research Assistant

AI chat, annotations, notes & similar papers

Finding related papers...

Discussions

(0)

No comments yet

Be the first to share your thoughts!